SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-229453
Filing Date
2024-10-01
Accepted
2024-10-01 06:16:51
Documents
14
Period of Report
2024-09-30
Items
Item 1.03: Bankruptcy or Receivership
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d850551d8k.htm   iXBRL 8-K 29946
2 EX-99.1 d850551dex991.htm EX-99.1 24302
  Complete submission text file 0001193125-24-229453.txt   182512

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigrq-20240930.xsd EX-101.SCH 2515
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigrq-20240930_lab.xml EX-101.LAB 17957
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigrq-20240930_pre.xml EX-101.PRE 11240
17 EXTRACTED XBRL INSTANCE DOCUMENT d850551d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 241341193
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)